Home > Insider Trading > Filing (0001104659-20-129040)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1442836	Mersana Therapeutics Inc.	MRSN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1709775	B Timothy Lowinger	C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139	Chief Science & Tech. Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-11-20	1,874	$3.51	1,874	No	4	M	Direct
Common Stock	Disposition	2020-11-20	1,874	$23.06	0	No	4	S	Direct
Common Stock	Acquisiton	2020-11-20	2,227	$6.16	2,227	No	4	M	Direct
Common Stock	Disposition	2020-11-20	2,227	$23.06	0	No	4	S	Direct
Common Stock	Acquisiton	2020-11-20	1,875	$3.51	1,875	No	4	M	Direct
Common Stock	Disposition	2020-11-20	1,875	$23.04	0	No	4	S	Direct
Common Stock	Acquisiton	2020-11-20	2,227	$6.16	2,227	No	4	M	Direct
Common Stock	Disposition	2020-11-20	2,227	$23.04	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-11-20	1,874	$0.00	1,874	$3.51
Common Stock	Stock Option (right to buy)	Disposition	2020-11-20	2,227	$0.00	2,227	$6.16
Common Stock	Stock Option (right to buy)	Disposition	2020-11-20	1,875	$0.00	1,875	$3.51
Common Stock	Stock Option (right to buy)	Disposition	2020-11-20	2,227	$0.00	2,227	$6.16

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
32,803	2029-01-22	No	4	M	Direct
108,362	2030-01-14	No	4	M	Direct
30,928	2029-01-22	No	4	M	Direct
106,135	2030-01-14	No	4	M	Direct

Footnotes

Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020.
This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.605 to $23.37, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any other security holder of Mersana Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.60 to $23.37, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any other security holder of Mersana Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019.
The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 15, 2020.